O
TEVA icon

OppenheimerFunds’s Teva Pharmaceuticals TEVA Stock Holding History

OppenheimerFunds’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,000
Closed -$24K – 956
2013
Q3 		$24K Buy
+3,000
New +$117K ﹤0.01% 910

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

OppenheimerFunds's TEVA Position: Q4 2018 in Review

OppenheimerFunds sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 4,233,132 shares — an estimated $91.2M sold.

OppenheimerFunds first reported a position in TEVA in Q2 2013 and held it in 21 quarters. The position peaked at $176M in Q4 2015. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • OppenheimerFunds reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • OppenheimerFunds sold 4,233,132 Teva Pharmaceuticals shares in Q4 2018, an estimated $91.2M.
  • OppenheimerFunds first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 21 quarters.
  • OppenheimerFunds's Teva Pharmaceuticals position peaked at $176M in Q4 2015.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on OppenheimerFunds's 13F filing for Q4 2018, filed 11 Feb 2019.